Billiontoone Inc (BLLN) Stock Forecast & Price Target

BillionToOne is supported by differentiated molecular diagnostics technology, with UNITY, Northstar Select, and Northstar Response leveraging QCT to deliver ultrasensitive testing, single-molecule quantification, and workflow advantages that competitors struggle to match. Its fundamentals appear strong, as Q1'26 revenue reached $108.4M (+84% Y/Y), gross margin was 73%, GAAP operating margin was 16%, adjusted EBITDA margin was 24%, and cash was $537M, while Q2 prenatal volumes still grew ~31% Y/Y to ~181k despite temporary payor-related headwinds. The outlook remains positive because demand and share gains continue, payer coverage has expanded to ~300M lives, and catalysts such as UNITY Confirm, Epic Aura integration, and the planned MRD launch should support utilization and revenue growth while preserving profitability.

BillionToOne is facing a negative fundamental setup because its strong top-line growth is being offset by rising operating expenses and a weaker profitability trajectory, with 2026 operating expenses raised to $293M and adjusted EBITDA margin cut from 21% to 15%. Although management reaffirmed its 2026 revenue guide of $450M-$465M and the business is still expanding, the outlook shows lower product revenue per test and margin pressure across 2027 and 2028, including revenue estimates of $580M and $780M with gross margins slipping to 70% in 2028. The stock also carries meaningful execution and competitive risks tied to reimbursement complexity, dependence on senior management, legal/IP protection, and uncertainty around how defensible its prenatal and oncology growth will remain as competitors challenge its platforms.